Home » Topics » Regulatory » EMA

EMA
RSS

Clinical development of Pluristem Therapeutics' PLX-PAD advances

Jan. 28, 2011

E.U. orphan drug status recommended for ALN-TTR01 in familial amyloidotic polyneuropathy

Jan. 27, 2011

CHMP recommends approval of Pravafenix

Jan. 26, 2011

CHMP recommends new indications of INOmax

Jan. 25, 2011

CHMP recommends European marketing authorization for Trobalt

Jan. 25, 2011

CHMP issues positive opinion on Eisai's Halaven for metastatic breast cancer

Jan. 25, 2011

CHMP decides against approval of Fampyra to improve walking in MS

Jan. 24, 2011

CHMP recommends approval of Jevtana combination regimen for prostate cancer

Jan. 24, 2011

CHMP adopts final negative opinion for cladribine tablets in relapsing-remitting MS

Jan. 24, 2011

CHMP adopts positive opinion for Gilenya in relapsing-remitting MS

Jan. 24, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 16, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...